MMP-2/MMP-9 Inhibitor II

TargetMol
Product Code: TAR-T36712
Supplier: TargetMol
CodeSizePrice
TAR-T36712-1mg1mg£243.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-5mg5mg£547.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-1mL1 mL * 10 mM (in DMSO)£561.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-10mg10mg£752.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-25mg25mg£1,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-50mg50mg£1,460.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-100mg100mg£1,942.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36712-500mg500mg£3,838.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
BPHA is a potent, selective and orally active inhibitor of MMP-2, MMP-9 and MMP-14 with IC50s of 12 nM, 16 nM and 17 nM, respectively.BPHA does not inhibit MMP-1, -3 and -7 (IC50s of 974, >1000 and 795 nM, respectively).BPHA has anti-angiogenic and BPHA has anti-angiogenic and anti-tumor activities.
CAS:
193807-60-2
Formula:
C21H20N2O4S
Molecular Weight:
396.5
Pathway:
Proteases/Proteasome
Purity:
0.98
SMILES:
O=S(C(C=C1)=CC=C1C2=CC=CC=C2)(N[C@@H](C(NO)=O)CC3=CC=CC=C3)=O
Target:
MMP

References

Kohri T, et al. Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor. Graefes Arch Clin Exp Ophthalmol. 2003;241(11):943-952. Maekawa R, et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999;59(6):1231-1235. Maki H, et al. Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model. Gan To Kagaku Ryoho. 1999;26(11):1599-1606.